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Abstract
Background: Toll-like receptor 3 (TLR3) is a critical component of the innate immune response
to dsRNA viruses, which was considered to be mainly expressed in immune cells and some
endothelial cells. In this study, we investigated the expression and proapoptotic activity of TLR3 in
human and murine tumor cell lines.
Methods: RT-PCR and FACS analysis were used to detect expression of TLR3 in various human
and murine tumor cell lines. All tumor cell lines were cultured with poly I:C, CHX, or both for 12
h, 24 h, 72 h, and then the cell viability was analyzed with CellTiter 96® AQueous One Solution,
the apoptosis was measured by FACS with Annexin V and PI staining. Production of Type I IFN in
poly I:C/CHX mediated apoptosis were detected through western blotting. TLR3 antibodies and
IFN-β antibodies were used in Blockade and Neutralization Assay.
Results: We show that TLR3 are widely expressed on human and murine tumor cell lines, and
activation of TLR3 signaling in cancerous cells by poly I:C made Hela cells (human cervical cancer)
and MCA38 cells (murine colon cancer) become dose-dependently sensitive to protein synthesis
inhibitor cycloheximide (CHX)-induced apoptosis. Blockade of TLR3 recognition with anti-TLR3
antibody greatly attenuated the proapoptotic effects of poly I:C on tumor cells cultured with CHX.
IFN-β production was induced after poly I:C/CHX treatment and neutralization of IFN-β slightly
reduced poly I:C/CHX -induced apoptosis.
Conclusion: Our study demonstrated the proapoptotic activity of TLR3 expressed by various
tumor cells, which may open a new range of clinical applications for TLR3 agonists as an adjuvant
of certain cancer chemotherapy.
Background
Toll-like receptor 3 (TLR3) is the critical sensor of the
innate immune system that serves to identify viral double-
stranded RNA (dsRNA). TLR3 was reported to be
expressed on immune cells and some certain nonin-
mmune cells, such as keratinocytes [1] or endothelial cells
[2]. TLR3 agonist polyinosinic-polycytidilic acid (poly
I:C) represents either genomic or life cycle intermediate
material of many viruses, and activates the immune cells
through binding both to the dsRNA-dependent protein
kinase (PKR) and TLR3. Double-stranded RNA has been
proved to induce apoptosis in several cell types through
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multiple pathways. For instance, dsRNA-transfected pan-
creatic  β-cells manifests PKR- and caspase-dependent
apoptosis [3,4], whereas endothelial cell apoptosis trig-
gered by exogenous dsRNA is mostly dependent on the
extrinsic caspase pathway [5,6]. As involvement of Toll/IL-
1R domain-containing adapter inducing IFN-β (TRIF) in
apoptosis has recently been suggested [7,8], TLR3 signal-
ing pathway is found to not only participate in limiting
virus replication but also cause infected cells to undergo
apoptosis, which is another way of protecting the host
against microbe spreading [9].
With the aim of inducing an IFN-mediated anticancer
immune response, both poly I:C and poly A:U have been
used with moderate success as adjuvant therapy in clinical
trials for different types of cancer [10,11]. Recently, Bruno
and his colleagues reported that TLR3 was expressed in
several breast cancer cell lines and could directly drive
those cells to apoptosis [12]. Here, we extensively ana-
lyzed the expression and proapoptotic activity of TLR3 in
a variety of human and murine tumor cells, and further
confirmed that TLR3 are widely expressed on human and
murine tumor cells. We then found that activation of
TLR3 signaling in cancerous cells by poly I:C made human
and murine cancer cells become sensitive to protein syn-
thesis inhibitor cycloheximide (CHX)-induced apoptosis,
and blockade of TLR3 recognition with anti-TLR3 anti-
body greatly attenuated the apoptosis-improving effects
of poly I:C on tumor cells.
Methods
Cell Lines and Reagents
The human tumor cell lines Hela (cervical cancer), A549
(small cell lung carcinoma), Hep2 (laryngeal carcinoma),
HepG2 (hepatoma), HO8910 (ovarian epithelial carci-
noma), and the murine cell lines B16 (melanoma), RM1
(prostate cancer), LLC (lung cancer), MCA38 (colon can-
cer), Hepa1-6 (hepatocellular carcinoma) were obtained
from American Type Culture Collection (ATCC, Rockville,
MD, U.S.A.). Polyinosinic-polycytidilic acid (poly I:C)
and cycloheximide (CHX) was purchased from Sigma-
Aldrich Co. Ltd (St. Louis, MO, USA).
Cell Cultures
Tumor cells were maintained in 2 ml RPMI 1640 plus
10% (v/v) heat-inactivated fetal bovine serum (FCS,
GIBCO, Grand Island, NY) in 6-well plates (Costar, Aus-
tria) at 2 × 105 cells/well. All of the media were supple-
mented with 2 mML-glutamine, 100 units/ml penicillin
G, 100 units/ml streptomycin. Cells were maintained at
37°C in a humidified incubator containing 5% CO2. Poly
I:C was used at the concentrations indicated. CHX was
added to the media at the concentration of 1.5 μg/ml.
RT-PCR Analysis
Total RNA was isolated from tumor cells using TRIzol rea-
gent according to manufacture's guide (Invitrogen,
Carlsbad, CA). Cellular RNA (1 μg) was reversedly tran-
scribed into cDNA in a reaction mixture containing 5 mM
MgCl2, 1 mM dNTP, 2.5 μM oligo (dT) primer, 1U RNase
inhibitor, and 2.5U reverse transcriptase (Invitrogen).
After incubation at 37°C for 50 min, the reaction was ter-
minated by heating at 70°C for 15 min. PCR primers for
detecting mRNA for TLR3 and β-actin were synthesized by
Sangon Ltd, Shanghai, China. Primer sequences were as
follows: human β-actin, sense, 5'-GTG GGG CGC CCC
AGG CAC CA-3', antisense 5'-CTC CTT AAT GTC ACG
CAC GAT TT-3'; human TLR3, sense, 5'-AAC GAT TCC TTT
GCT TGG CTT C-3', antisense 5'-GCT TAG ATC CAG AAT
GGT CAA G-3'; mouse β-actin, sense, 5'- ATG GAT GAC
GAT ATC GCT -3', antisense, 5'- ATG AGG TAG TCT GTC
AGG T -3'; mouse TLR3, sense, 5'-AAG AGG GCG GAA
AGG TG-3', antisense, 5'-GAA GCG AGC ATT TAC TA-3'.
The PCR reaction buffer (25 μl), consisting of 2 mM
MgCl2, 0.5 μM of each primer, and 1U Ampli Taq DNA
polymerase, was added to an amplification tube. PCR was
run for 35 cycles. Each cycle consisted of 95°C for l min,
55°C for l min, and 72°C for l min.
Flow Cytometric Analysis
To detect cell surface expression, cultured human tumor
cells were stained with purified anti-human TLR3 anti-
body (eBioscience, San Diego, CA) or purified Mouse
IgG1 control (eBioscience), followed by FITC-conjugated
rat anti-mouse IgG1 mAb (clone A85-1, BD PharMingen,
San Diego, CA). The Murine tumor cells were stained with
rat serum anti-mouse TLR3 (eBioscience) or purified rat
IgG isotype control (eBioscience), followed by FITC-con-
jugated F(ab')2 goat anti-rat IgG (Caltag Laboratories,
South San Francisco, CA). To analyze intracytoplasmic
TLR3 expression, tumor cells were prefixed and permeabi-
lized. The following staining treatments were the same as
above. Finally, stained cells were analyzed by using a flow
cytometer (FACScalibur, Becton Dickinson, Franklin
Lakes, NJ, USA), and the data were processed with
WINMDI2.9 software.
Cell Viability Analysis
Cell viability was determined by Cell-titer 96 aqueous one
solution cell proliferation assay kit (Promega, Madison,
WI, USA). The process of the experiment is completely
according to the instruction. Briefly, aliquots of 1 × 103
cells/well were cultured in 96-well plates (Costar, Austria)
with or without Poly I:C/CHX for 72 h. Poly I:C was used
at the concentrations of 100 μg/ml. CHX was added at the
concentrations of 1.5 μg/ml. 40 μl of Cell-titer 96 aqueous
one solution were added to each well and incubated for
an additional 3 h. The absorbance at 490 nm was recordedBMC Cancer 2008, 8:12 http://www.biomedcentral.com/1471-2407/8/12
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with a 96-well plate reader. Each experiment was per-
formed in triplicate and repeated at least three times.
Apoptosis Assays
2 × 105 tumor cells were washed twice with cold PBS, fol-
lowed by being resuspended in 100 binding buffer (10
mM HEPES-NaOH, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) and then incubated with 4 μl FITC-conjugated
annexin-V and 5 μl Propidium iodide (PI) from BD
PharMingen (San Diego, CA) in dark for 20 min at room
temperature. Samples were immediately analyzed with
flow cytometry. The stained cells were also analyzed by a
FACScalibur flow cytometer (Becton Dickinson).
Western Blot Analysis
Hela cells and MCA38 cells were stimulated with poly I:C/
CHX for 3 hours, 6 hours, 9 hours or 12 hours respec-
tively. Cellular extracts were prepared as described [13].
Protein samples were mixed in Laemmli loading buffer,
boiled for 5 min, and then subjected to 14% SDS-PAGE.
After electrophoresis, proteins were transferred onto
PVDF membrane (Millipore, Billerica, MA). The blots
were incubated with rabbit anti-mouse or human IFN-β
polyclonal antibody (PBL Biomedical Laboratories) over-
night at 4°C. Membranes were washed with 0.05% (vol/
vol) Tween 20 in PBS (pH 7.6) and incubated with a
1:3000 dilution of Horseradish peroxidase (HRP) linked
anti-rabbit IgG secondary antibody (Promega) for 60 min
at room temperature. Protein bands were visualized by
ECL substrate (Pierce).
TLR3 Blockade and IFN-β Neutralization Assay
Hela cells and MCA38 cells were maintained in 12-well
plates (Costar, Austria) at 1 × 105 cells/well. In TLR3
Blockade assay, Hela cells were treated with the purified
anti-human TLR3 antibody (eBioscience) at the concen-
tration of 10 μg/ml for 4 hours before being stimulated
with poly I:C/CHX. The treatment of MCA38 cells is iden-
tical to Hela cells except for the rat serum anti-mouse
TLR3 antibody (eBioscience) we used. In IFN-β Neutrali-
zation assay, Hela cells or MCA38 cells were treated with
anti-human IFN-β antibody (PBL Biomedical Laborato-
ries) or anti-mouse IFN-β antibody (PBL Biomedical Lab-
oratories) at the concentration of 1 × 104 U/ml for 4 hours
before being stimulated with poly I:C/CHX.
Statistical Analysis
Data are expressed as the means ± SD with n = 3. Statistical
significances were determined with use of the unpaired
Student's t test (P values < 0.05). All data from cell culture
experiments are on the basis of at least three individual
cell preparations.
Results
Toll-like receptor3 was widely expressed in human and 
murine tumor cells
we screened various human and murine tumor cell lines
from different tissues, including human cell line Hela
(cervical cancer), A549 (lung carcinoma), Hep2 (laryn-
geal carcinoma), HepG2 (hepatoma), HO8910 (ovarian
epithelial carcinoma), and murine cell line B16
(melanoma), RM1(prostate cancer), LLC (lung cancer),
MCA38 (colon cancer), Hepa1-6 (hepatocellular carci-
noma) for the expression of TLR3 by RT-PCR (Fig 1A) and
FACS analysis (Fig 1B, C). We found that all these tumor
cell lines expressed TLR3 mRNA. FACS analysis showed
that TLR3 was present both inside the cells and on the cell
surface, but the expression on the protein level is dis-
tinctly higher in Hela, A549 and MCA38 cells.
Poly I:C treatment caused tumor cells more sensitive to 
CHX-induced cell death
To investigate the effects of TLR3 on tumor cells, all tumor
cell lines were pre-cultured with 100 μg/ml of poly I:C, a
ligand of TLR3, for 72 h, and then cell viability was ana-
lyzed. Unexpectedly, few tumor cell lines tested showed a
significant decrease in cell viability after treatment with
poly I:C alone (all less than 10%, data not shown). How-
ever, cell viability of protein synthesis inhibitor cyclohex-
imide (CHX)-treated tumor cells (Hela cells and MCA38
cells) became dramatically lower in the presence of poly
I:C (Fig 2). We also compared the expression level of TLR3
in poly I:C- or CHX- treated Hela cells and MCA38 cells
with PBS-treated control cells, but found no remarkable
changes (see Additional file 1).
Poly I:C dose-dependently increased CHX-induced 
apoptosis of tumor cells
We then examined the apoptosis of a variety of human
and murine tumor cells by double-staining of Annexin V
and PI. All tumor cells incubated in poly I:C alone even in
high concentrations (up to 100 μg/ml) showed minimal
apoptosis. Likewise, CHX alone (1.5 μg/ml) had no signif-
icant effect on these tumor cell lines. However, when
incubated in the presence of both CHX and Poly I:C, the
Annexin V/PI positive tumor cells significantly increased
in the Hela cells and MCA38 cells (Hela and MCA38 up to
about 40% and 70% respectively, Fig 3A, 3B), and few
other tumor cell lines tested showed notable differences
between apoptosis of tumor cells stimulated with CHX
alone or poly I:C/CHX (data not shown). We still found
that the induction of the apoptosis was dose-dependent
but not time-dependent (Fig 3C). These findings sug-
gested that tumor cells death is related to poly I:C-
improved CHX-induced apoptosis.BMC Cancer 2008, 8:12 http://www.biomedcentral.com/1471-2407/8/12
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Blockade of TLR3 recognition attenuated the apoptosis-
improving effects of poly I:C on tumor cells
As double-stranded RNA has also been proved to induce
cell apoptosis through PKR pathway, we use antibody to
block TLR3 signaling in order to prove that the poly I:C-
enhanced tumor cells apoptosis is mediated by TLR3. The
results showed that blockade of TLR3 recognition with
anti-TLR3 antibody greatly attenuated the apoptosis-
improving effects of poly I:C on tumor cells (Fig 4).
Type I IFN was involved in the apoptosis-improving effects 
of poly I:C on tumor cells
Because several studies reported that the production of
IFN-β was required in cell apoptosis induced by TLR3 ago-
nists [14,15], we evaluated the role of type I IFN in poly
I:C/CHX mediated apoptosis. Western blot result showed
that both human and murine IFN-β productions of Hela
cells and MCA38 cells were mildly induced after 9 h of
poly I:C/CHX treatment (Fig 5A). Neutralization of IFN-β
Expression of TLR3 in tumor cells Figure 1
Expression of TLR3 in tumor cells. (A). Expression of TLR3 in different human and mouse tumor cell lines was analyzed by RT-PCR. One representa-
tive experiment (out of three) is depicted. (B, C). FACS analysis of intracellular(B) and cell surface(C) expression of TLR3 in tumor cell lines. Histograms 
showed TLR3 expression (shadow area) with isotype controls (black lines).
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with antibodies since the tumors were stimulated slightly
reduced poly I:C/CHX -induced apoptosis (Fig 5B), sug-
gesting that IFN-β was involved in TLR3-triggered cytotox-
icity.
Discussion
TLR3 was thought to be mainly expressed in immune
cells, keratinocytes and some endothelial cells. Recently, it
has been reported that certain human tumor cells also
express this receptor [12,16]. Our work shows that TLR3 is
widely expressed in human and murine tumor cells lines
from different origin though at different levels, suggesting
that TLR3 activation may play important functions in
tumor biology.
Ligation of TLR3 and its ligand dsRNA triggers well-char-
acterized signaling cascades that result in activation of
downstream effectors, such as NF-κB, p38, JNK, and IFN
regulatory factors (IRFs) 4 [17]. Many of these signaling
elements are also involved in tumor growth and apopto-
sis, implying that TLR3 expressed in tumor cells may also
affect tumor viability. In the present study, we investigated
the response of tumor cell lines from different origin in
vitro to the stimulation with TLR3 agonist poly I:C and
the tumor chemotherapeutic drug CHX. We found that
incubating tumor cells with CHX alone in the used dosage
or poly I:C alone showed no significant effects on cancer
cell viability. However, incubation of human Hela cells or
murine MCA38 cells with CHX plus poly I:C caused dra-
matically apoptosis of these cells in a poly I:C dose-
Tumor cell apoptosis after treatment with poly I:C and CHX Figure 3
Tumor cell apoptosis after treatment with poly I:C and CHX. (A) FACS analysis of apoptosis in Hela and MCA38 cells after stimulation with poly 
I:C and CHX. Tumor cells were cultured for 24 h with PBS, poly I:C (100 μg/ml), CHX (1.5 μg/ml) or poly I:C puls CHX, and apoptosis was measured by 
Annexin V, PI staining. (B) Statistic analysis of apoptotic cells based on Fig 1A. (C) The dynamic analysis of apoptosis of tumor cells. Cancer cells (Hela or 
MCA38) were cultured with different concentrations of poly I:C (50 or 100 μg/ml) and the same concentration of CHX (1.5 μg/ml) for 12 h or 24 h. PBS 
was used as control. Apoptosis was measured by flow cytometry with anti-Annexin V and anti-PI antibodies. Data were obtained from three independent 
experiments.
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dependent manner via TLR3 pathway, which is confirmed
by our TLR3 blockade assay. Several studies have reported
that molecular events involved in cell death induced by
TLR3 agonists include the production of IFN-β[14,15]
required for apoptosis. In our study, we also found that
IFN-β production of tumor cells could be induced by poly
I:C/CHX stimulation, which might function as a proapop-
totic agent by up-regulating the expression of proteins
directly involved in cell death, including caspases [18],
TRAIL [19,20], and p53 [21] as reported. On the other
hand, partly reduction of poly I:C/CHX -induced apopto-
sis in the neutralization assay of IFN-β suggested other
pathway involved. Thus roles of proteins such as TBK1
and RIP1, which all participate in TLR3 signaling [22] will
require additional studies. Since Salaun has recently
proved that in contrasts with its survival role after TLR2
[23]and TLR4 [24] triggering, NF-κB appears to be neces-
sary for TLR3-mediated apoptosis [12], it would be inter-
esting to investigate how NF-κB links TLR3 triggering and
CHX stimulating to apoptosis pathway.
Besides TLR3, PKR, the cytoplasmic helicase family pro-
teins (retinoic acid-inducible gene I (RIG-I) and
melanoma differentiation-associated gene 5 (MDA5))
also serve as dsRNA pattern-recognition receptors [1,25],
which are reported to trigger different signaling pathways
from TLR3 [26]. Although blockade of TLR3 markedly
reduced apoptosis of tumor cells treated by poly I:C/CHX,
we can not completely exclude the possibility that RIG-I/
MDA5 contributed to the recognition of poly I:C internal-
ized by endocytosis. Moreover, unpublished result of our
Neutralization of IFN-β partly attenuates poly I:C-improved tumor apoptosis Figure 5
Neutralization of IFN-β partly attenuates poly I:C-improved tumor apoptosis. (A) IFN-β protein level is measured by WB in lysates of Hela 
cells or MCA38 cells cultured with poly I:C/CHX for the indicated time periods. β-actin is shown as a loading control. (B) Hela cells or MCA38 cells were 
treated with anti-human IFN-β antibody or anti-mouse IFN-β antibody at the concentration of 1 × 104 U/ml for 4 hours before being stimulated with poly 
I:C (100 μg/ml)/CHX (1.5 μg/ml) for 12 hours. Apoptosis were determined as above. The data is presented as the mean ± SD.
Control
poly I:C
CHX
poly I:C+ CHX
Control
poly I:C
CHX
A.  B. 












Hela
MCA38
%
 
a
p
o
p
t
o
s
i
s
 
c
e
l
l
s

	
	


	



Hela MCA38
Β-actin
Β-actin
Β-actin
Β-actin
IFNΒ
IFNΒ
IFNΒ
IFNΒ
poly I:C+ CHX
TLR3 blockade attenuates poly I:C-improved tumor apopto- sis Figure 4
TLR3 blockade attenuates poly I:C-improved tumor apoptosis. 
Hela cells or MCA38 cells were treated with purified anti-human TLR3 
antibody or anti-mouse TLR3 antibody at the concentration of 10 μg/ml 
for 4 hours before being stimulated with poly I:C (100 μg/ml)/CHX (1.5 
μg/ml) for 12 hours. Apoptosis were determined as above. The data is 
presented as the mean ± SD.
%
 
a
p
o
p
t
o
s
i
s
 
c
e
l
l
s
%
 
a
p
o
p
t
o
s
i
s
 
c
e
l
l
s
















Hela MCA38

	
	


	


BMC Cancer 2008, 8:12 http://www.biomedcentral.com/1471-2407/8/12
Page 7 of 8
(page number not for citation purposes)
study on the apoptosis in other tumor cell lines trans-
fected with vector expressing poly I:C demonstrated the
involvement of RIG-I/MDA5 pathway.
It is still largely unknown how CHX induces tumor cells
cytotoxicity in the presence of poly I:C, although we fig-
ured out the production of IFN-β involved. Furthermore,
there were still some cell lines we tested insensitive to poly
I:C, CHX or both, which can be explained by defects in the
cellular apoptotic machinery or low expression levels of
TLR3.
Since both poly I:C and poly(A:U) have been used with
moderate success as immune adjuvant therapy in clinical
trials for different types of cancer [27], including adeno-
carcinomas of the breast [28], our findings may open a
new range of the applications for TLR3 agonists as an
adjuvant of cancer chemotherapy.
Conclusion
We have described the proapoptotic activity of TLR3
expressed by various tumor cells, uncovered the associa-
tion of TLR3 signaling with protein synthesis inhibition in
tumor cells. Our study may open a new range of therapeu-
tic applications for TLR3 agonists as a adjuvant of chemo-
therapy drugs in some certain cancers.
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